TB

The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB.

This document provides specific guidance for screening and post- screening management of all people who have been identified through public health investigations as having been exposed to multidrug resistant tuberculosis (MDR TB). Recommendations for symptomatic contacts, children less than 5 years of age and those who are highly immunocompromised (see step 1B) are different from other groups.

This material was developed for clinicians to use with patients that are prescribed the three months of daily isoniazid plus rifampin (3HR) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 3HR regimen.

The patient education brochure was developed for clinicians to use with patients while discussing the 12-dose regimen for the treatment of latent TB infection. The brochure contains information on latent TB infection, the 12-dose regimen, and adverse events.

The handout describes the main characteristics of LTBI and Active TB, as well as their differences. The material also describes what increases the risk for developing Active TB and how to prevent TB from developing. English is on one side and Russian is on the other.

This material was developed for clinicians to use with patients that are prescribed the three months of daily isoniazid plus rifampin (3HR) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 3HR regimen.

This material was developed for clinicians to use with patients that are prescribed the four months daily rifampin (4R) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 4R regimen.

This guidebook can be used by primary care clinics and other partners to assist with strengthening their setting’s TB prevention activities. The guidebook was developed by staff from the TB Free California initiative, a project of the California Department of Public Health.

This toolkit is designed for health department staff responsible for planning and conducting TB contact investigations in school settings. The toolkit provides guidance, tips, and tools for planning and implementing a school TB contact investigation.

A toolbox of TB resources for public health programs. Resources include LTBI education materials, California TB legal resources, World TB Day resources, and more.